Remove Clinical Development Remove Protein Expression Remove Small Molecule Remove Vaccine
article thumbnail

Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions

The Pharma Data

CD40-ligand is a protein expressed on the surface of activated T lymphocytes that mediates T cell helper function. CD40-ligand is also known as CD154, the T cell-B cell activating molecule (T-BAM), TRAP and gp39. 175:1091-1101 (1992) 2 Karpusas, M et al., International Immunol. (11):1583 Structure. 9(4):321-9.

article thumbnail

Present Treatments & Hopeful Future Directions for ALS Pharmacotherapies

Conversations in Drug Development Trends

Differences in regulatory sentiments and industry sponsors’ subsequent clinical development strategies historically restricted access based on geography. However, work is needed before CRISPR-mediated treatments become possible, including a better understanding of the genes involved in ALS.

article thumbnail

What to expect from PEGS Europe 2023: Day 3

Drug Discovery World

Next-generation immunotherapies The fourth track of PEGS Europe 2023 on the third day is ‘Next-generation immunotherapies’, which will feature a range of sessions made up of presentations, talks and posters which address cell-based immunotherapies, vaccines, and checkpoints and agonists.